Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · malnourished or nutritionally at‐risk adults
1 finding from 1 review
Adverse events Self‐reported outcomes
Psychological interventions showed no clear difference in adverse events Self‐reported outcomes compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Intervention vs alpha‐glucosidase inhibitors [30 weeks] · participants with type 2 diabetes mellitus
The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.63 [0.52, 0.76]
1 study · 2 participants
Low
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events Interventions vs thiazolidinediones [1. 6 months to 12 months] [2. 24 weeks to 52 weeks] · participants with type 2 diabetes mellitus
The intervention may leads to lower adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.88 [0.78, 0.99]
1 study · 3 participants
Low
Intervention not reported
Adverse events 1. All adverse events 2. Drop‐outs due to adverse events 3. Severe hypoglycaemia a. Intervention vs placebo [1a. 24 weeks] [2a. 24 weeks to 56 weeks] b. Intervention vs metformin [1b. 6 months to 4 years] [2b. 24 weeks to 4 years] [... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in adverse events 1. All adverse events 2. Drop‐outs due to adverse… (low certainty).
1 finding from 1 review
RR 0.91 [0.51, 1.62]
1 study · 2 participants
Low
Adverse events · adults
1 finding from 1 review
Adverse events · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes adverse events compared with preoperative pharmacological therapy and surgery (very low certainty).
1 finding from 1 review
Adverse events · adults with growth‐hormone secreting pituitary adenomas
It is very uncertain whether surgery alone changes adverse events compared with pharmacological therapy alone (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · adolescents (aged 12‐17 years) being overweight or obese
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Adverse events · adults with type 2 diabetes and severe mental illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity
1 finding from 1 review
Intervention not reported
Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · patients with LADA
1 finding from 1 review
Serious adverse events · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
1 finding from 1 review
Serious adverse events (N) · people at increased risk for developing type 2 diabetes
Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).
1 finding from 1 review